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ABStrAct
The article aims to draw attention of clinicians to the addictive potentials of Pentazocine use 
in sickle cell anaemia patients and to highlight some of the associated problems of pentazocine 
abuse. It also hopes to stimulate the need to review guidelines for the use of analgesics in the man-
agement of bone pain crisis or other chronic pains. Two case reports of pentazocine abuse seen in 
a psychiatry clinic at the University of Ilorin Teaching Hospital (UITH) Ilorin, Nigeria were made. 
It was found that both patients who were sickle cell anaemia (HbS) patients were first given intra-
muscular pentazocine in private hospitals during an episode of bone pain crises. They claimed that 
though the bone pain crises subsided after a few days on admission, they continued to feign pains 
in order to be given pentazocine because they enjoyed its dysphoric effect. There were features of 
pentazocine dependence as shown by intense craving for the drug, excessive sweating, body (not 
bone) pains, signs of needle pricks on the body, sudden extravagance, begging for money, stealing 
and poor academic performance among other things. There was no clinical evidence of bone crisis 
or complications of sickle cell anaemia. It was concluded that more than before, clinicians should 
be cautious in the use of analgesics which has potential for addiction in sickle cell anaemia and 
chronic pain patients.
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introDuction
In Nigeria, Pentazocine is commonly used 
in the management of surgical and chronic 
pains. It is especially used in the manage-
ment of bone pain crisis of sickle cell anae-
mia. Pentazocine is a narcotic agonist/antago-
nist analgesic derived from benzmorphinan. 
It is an opioid drug developed in 1967 as a 
result of efforts to find an effective but less 
dependence-producing analgesic when com-
pared with morphine. It produces little or no 
euphoria but has some dysphoric effect in a 
few individuals (Lang & Pilon, ). It was ini-
tially thought to be non-addictive, but its po-
tential for abuse was soon realized (Weber & 
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Fromme, 1970; Huskisson, 1974). Since then, 
various efforts have been made to reduce its 
abuse including the production of a brand 
that contains enough antagonist (naloxone) to 
counteract its effect, if the tablet is dissolved 
and injected. An example of this brand is Tal-
win Nx. Other efforts include the classification 
of Pentazocine as a controlled drug in some 
countries such as United States of America 
where it is classified under Schedule IV in the 
Controlled Substances Act. 
The earliest data on substance use and 
abuse in Nigeria emanated in the 1960s, and 
were hospital based (Asuni, 1964; Lambo, 
1965). Thus, Lambo in 1965 reported 18 cases 
of cannabis abuse out of 4000 patients seen in 
Neuropsychiatric Hospital, Abeokuta, Nigeria. 
Also, Asuni in 1964 reported cannabis abuse 
in 13 out of 380 patients discharged from Neu-
ropsychiatric Hospital, Yaba, Lagos, Nigeria. 
Since then, there had been reports on substance 
use and abuse in Nigeria. While some were 
hospital based (Adelekan & Adeniran, 1988; 
Ohaeri & Odejide, 1991), others were com-
munity based (Anumonye, 1980; Onibokun 
et al, 1999). Some studies have focused on at-
risk groups such as secondary school students 
(Adelekan, 1989; Adelekan et al, 2001), un-
dergraduates (Frank & Edward, 1999; Adele-
kan et al, 2000) health workers (McAuliffe & 
Rohman, 1986). As a result of these studies, 
various drugs of abuse such as alcohol, to-
bacco, cannabis, stimulants, cocaine, heroin, 
hallucinogens e.t.c. have been documented. 
The frequency of use of some of these drugs 
tends to vary depending on, among other fac-
tors, their availability, accessibility and effec-
tiveness of legislation against them.  However, 
in Nigeria and most especially in the area of 
study, no documented report exists on the 
abuse of Pentazocine especially among sickle 
cell anaemia patients.  This report therefore is 
aimed at highlighting the addictive potential 
(and its associated problems) of Pentazocine 
use as an analgesic in patients with sickle cell 
anaemia and secondly to stimulate the need for 
review of guidelines for the use of analgesics 
in the management of bone pain crisis or other 
chronic pains.
MethoD
A report of two cases of pentazocine abuse 
seen in a psychiatry outpatient clinic in the 
University of Ilorin Teaching Hospital, Ilorin, 
Nigeria.  
case reports 
case one: Miss X is a 23-year-old Nigerian 
undergraduate with sickle cell anaemia whose 
electrophoretic pattern was HbS. She present-
ed on the 8th of June 2004 with one-year his-
tory of self-injection with Pentazocine. This 
started following her previous admission into 
a private hospital in Lagos on account of bone 
pain crisis. She claimed the pains was local-
ized mainly in the chest, hands and thighs. 
While on admission, she was treated with DF 
118, one tablet thrice daily, tramadol, one tab-
let when necessary and intramuscular pentazo-
cine 30mg once daily. Patient claimed though 
she was on pentazocine for about 45 days, 
she actually had bone pains only in the first 
one week of admission. She thereafter started 
feigning pain in order to be given pentazocine 
as she enjoyed its euphoric effect. After dis-
charge, she started self-administering pentazo-
cine. The most preferred site of self-injection 
was her thighs so that it could be hidden from 
her siblings and colleagues. While in school, 
she often sneaked into the emergency room of 
a nearby Teaching Hospital, picked up some 
prescription sheets (without permission), pre-
scribed Pentazocine using forged signatures 
and procured it from different pharmaceuti-
cal shops. Sometimes she bought Pentazo-
cine without prescription, as the pharmacy at-
tendants had known her over time. She spent 
about six hundred Naira (about $4.00) per 
day on Pentazocine alone. She sourced mon-
ey by taking loans from friends, exploiting 
her mother, and from strangers. Though she 
claimed she does not prostitute to get money 
for drugs, her younger sister claimed, on many 
occasions she had left the campus on trips with 
men. In the past eight months, patient claimed 
she was using Pentazocine on daily basis. De-
lay in procuring it causes running nose, severe 
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body pains, restlessness, insomnia and in-
tense craving for the drug. Each injected in-
tramuscular dose of 30mg lasts for about five 
hours. She claimed that the need for the drug 
has taken a primacy effect over other activi-
ties. Usually, her first dose for the day would 
be taken first thing in the morning while the 
second dose would be taken just before bed-
time. In spite of her awareness that she was 
already dependent, she could not voluntarily 
stop. The patient’s inability to voluntarily stop 
the drug and her inability to keep up with the 
cost of the needed doses per day prompted her 
to intimate a friend of her problems. She was 
taken to a medical Consultant/Clergyman who 
then referred her to a Consultant Heamatolo-
gist (P.O). The Haematologist assessed her and 
referred to a Psychiatrist (A.B). The two Units 
thereafter, co-managed the patient. 
On mental state examination, patient was 
well kempt, co-operative and appeared well 
motivated. She had rhinorrhea and was a bit 
restless. She claimed she was feeling cold and 
feverish in spite of the hot weather. She had 
no hallucinatory experiences or behaviour 
suggestive of such. There was no abnormal-
ity of stream, form, content and possession of 
speech. Her cognitive functions were within 
normal limits. She had a full insight. On physi-
cal examination, patient was slightly small for 
age, mildly icteric and had a slightly protrud-
ing abdomen. She had goose pimples and mul-
tiple hyperpigmented macules on the anterior 
aspects of both thighs (from needle pricks). 
A diagnosis of Pentazocine dependence 
was made and patient was admitted on to the 
medical ward for detoxification as the Teach-
ing Hospital, as at the time of this report, did 
not have a separate drug ward apart from the 
psychiatric ward. While on the ward, she was 
placed on oral Chlorpromazine 100mg b.d and 
oral Benzhexol 2.5mg b.d. In spite of the vigi-
lance by nurses and relatives, patient on several 
occasions still self-injected and purchased Pen-
tazocine by sending unsuspecting relations of 
newly admitted patients to purchase the drug 
for her. She often lied to them, claiming that 
she had been given an emergency prescription 
and her relations had not turned up to buy the 
drug for her. In view of these tricks, patient was 
transferred to the psychiatric ward a week from 
the date of admission.   On the psychiatry ward, 
she was monitored more closely and a chart de-
tailing her movement at all times was kept. She 
was not allowed access to writing materials and 
money.  She was discharged after 23 days hav-
ing satisfied some set goals such as presumed 
elimination of drug in the system, improved 
health and physical functioning and, reduction 
in potential hazard to public health and safety. 
This was based on patient’s response at clini-
cal interview sessions, counseling sessions and 
report from her confidant and closest relatives 
around (her younger sister). The Chlorprom-
azine and Benzhexol tablets were tapered off 
after two weeks post discharge.
case two: Mr Y is a 25-year-old Univer-
sity drop-out with sickle cell anaemia with 
HbS electrophoretic pattern. He is the last of 
three children all with sickle cell anaemia. The 
first is a male and a medical doctor who died 
about two years ago, while the second is a fe-
male who, patient claims, abuses Pentazocine 
also. Mother is a petty trader while father is 
a retired middle level civil servant. Patient 
was first seen on the 10th of February 2005 on 
account of four-year history of self-injecting 
with Pentazocine. Though patient had been 
given Pentazocine on a few occasions while 
on admission at the University of Ilorin Teach-
ing Hospital, he became addicted to the drug 
about four years ago when he was admitted at 
a private hospital in Lagos on account of osteo-
myelitis of the left mandible. While on admis-
sion, he claimed, he was given intramuscular 
Fortwin (Pentazocine) 30mg b.d and paren-
teral antibiotics for about 3 weeks. Thereafter, 
patient claimed, he continued to feign pain in 
the jaw and the thigh so that he could continue 
to be given Pentazocine as he enjoyed the ‘eu-
phoric experience’ the drug gave him. After 
discharge, patient presented at the Accident 
and Emergency Unit of University of Ilorin 
Teaching Hospital, Ilorin feigning bone pain 
crisis. He specifically requested the attending 
doctor to prescribe intramuscular Pentazocine, 
folic acid and chloroquine tablets. Patient’s ac-
cess to doctors was facilitated because most of 
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them knew his late brother as a colleague. This 
facilitated his chance of being given a prescrip-
tion without entering it into his case notes. 
This allowed him to have multiple prescrip-
tions within a short period of time without the 
doctors’ knowledge. At a point, some doctors 
became suspicious of his incessant complaints 
and would ask him to present at the sickle cell 
clinic. Thus, he started stealing prescription 
sheets and forging prescriptions. Most times, 
at the pharmacy stores, his prescription sheet 
will not be requested for or scrutinized as he 
was well known to the attendants.  
Patient claimed he self injects once daily, 
which translates to about 300 Naira ($2) per 
day. He sustains his drug habit through beg-
ging, especially from hospital workers and pa-
tients’ relatives. He also goes to public places 
with fake prescription sheet to beg for money 
and sometimes makes up to 200 to 500 Naira 
daily. He often stole and sold items from the 
house to make money. His persistent begging 
for money has made him a common feature 
on the corridors of the hospital until he was 
referred to the Psychiatrist for management. 
Patient expressed a wish to be treated for drug 
abuse (Pentazocine). He admitted that the drug 
behaviour had made him an object of ridicule 
at home and in the community. His academic 
records had also been negatively affected. He 
claimed he knew he was being ruined gradual-
ly by the drug yet he could not stop. He there-
fore readily accepted to being managed on the 
psychiatry ward.  
On mental state examination, patient was 
poorly kept, co-operative and appeared quite 
motivated. He was apprehensive but not rest-
less. He had no rhinorrhea or feverish feelings. 
Other aspects of mental state examination 
were essentially normal. On physical examina-
tion, he was markedly small for age and mildly 
jaundiced. He had multiple hyperpigmented 
macules (needle prick points) on the anterior 
and medial aspects of the cubital regions of 
both upper limbs. A diagnosis of Pentazocine 
dependence was made and patient was to be 
co-managed by the Psychiatry and Haema-
tology Units.  Since there was no drug ward, 
patient was detoxified on the psychiatry ward 
using oral Chlorpromazine 100m b.d. and oral 
Benzhexol 2.5mg b.d. Patient was discharged 
after three weeks having satisfied some set 
goals such as presumed elimination of drug in 
the system, improved health, reduction in po-
tential hazard to public health and safety. This 
was based on patient’s responses at clinical in-
terview sessions, counseling sessions and re-
port from relations and ward staff. He was re-
ferred to the outpatient clinic for continuation 
of counseling, rehabilitation and maintenance 
of drug free behaviour. 
DiScuSSion
Report of incidence and features of Penta-
zocine abuse in our environment has not been 
given enough priority.  Authors in other parts 
of the world had reported some features of ul-
cers that could indicate the use of pentazocine 
(Ghandi et al, 2004; Prasad et al, 2004). Based 
on the two cases presented, we suggest that, in 
a sickle cell anaemia patients, the presence of 
one or a combination of needle prick points, an 
increase in frequency of report of ‘bone pain 
crisis’ (usually a feigned pain) and a sudden 
non-prudence on financial matters should raise 
a suspicion of parenteral drug abuse until oth-
erwise proven.   
In the above two case vignettes, they were 
both exposed to the use of Pentazocine, an opi-
oid drug, subsequent to an episode of genuine 
need for the drug (bone pain crisis in the first 
case and oseomyelitis in the second case). It is 
worthy of note that the use of Pentazocine was 
prolonged (at least three weeks) in both cases. 
It was also observed that both cases continued 
to feign pain after genuine pain had subsided 
in order to continue to self-inject Pentazocine. 
At this point, it could be said that the patients 
were becoming addicted and needed the drug 
not for its pain relieving properties but for its 
euphoric effect. This will suggest a need for 
doctors taking care of patients with chronic 
pains to appreciate the difference between 
genuine and feigned pain. While this point may 
seem obvious, there is a need to caution that, 
to wrongly be on any side could be danger-
63
PENTAZOCINE ABUSE IN NIGERIA
ous. To wrongly assume a patient is feigning 
pain and therefore withhold potent analgesic is 
unethical and may unduly prolong suffering, 
whereas to assume the converse could as well 
predispose the patient into drug addiction. It is 
therefore pertinent for clinicians to set out for-
mal guidelines or charts for determining when, 
how and what analgesic to give while attending 
to different categories of pain disorders. Such 
protocol/guideline would need to be reviewed 
until the best of practice is achieved.   
The above cases also illustrate the accom-
panying dangers of drug dependence. On its 
own, the management of sickle cell anaemia 
may predispose a family to physical, psycho-
social and financial stress. The presence of a 
co-morbidity of sickle cell anaemia and drug 
dependence might further affect their clinical 
and psychological states. The dependent pa-
tient continues to inject Pentazocine in order 
to alleviate or eliminate withdrawal symp-
toms. To sustain and fund the drug habit, he/
she may engage in antisocial behaviours such 
as stealing, begging, lying, prostitution espe-
cially in females, and selling properties at ri-
diculous prices. These behaviours were exhib-
ited by the two cases cited above and could, if 
unchecked, further compromise their physical 
and mental health. There is therefore, a need to 
ensure careful use of analgesics with addictive 
potential in these patients in order to minimize 
societal cost of health. 
The patients were to go through two phases 
of treatment; detoxification and stabilization 
phase and, the rehabilitation and relapse pre-
vention phase. In the study centre, we could 
not detoxify patients using dose-tapered opi-
oid agonists such as methadone nor partial an-
tagonist such as buprenorphine or adrenergic 
agonist such as clonidine and lofedipine. In the 
alternative, and for calming effect the patients 
were placed on oral dose of chlorpromazine 
100mg twice daily to be adjusted according 
to clinical response. The Chlorpromazine was 
tailed off two weeks after discharge.
In spite of the limitations of facilities for 
substance and drug abuse management in the 
treatment centre, the authors have within the 
available resources managed these cases of 
Pentazocine abuse by dividing treatment into 
detoxification/stabilization and rehabilitation/
relapse prevention stages. While we could 
state that the patients had successfully gone 
through the detoxification/stabilization phase, 
plasma or urine pentazocine level monitoring 
would be needed to determine the degree of 
relapse prevention. Reports have shown that 
the proportion of patients using opioids (her-
oin) tend to drop from 17% to 6% after resi-
dential rehabilitation programmes (UNODC, 
2002). We would have referred the patients 
to self-help groups but we could not, as such 
groups do not exist in this environment. How-
ever, the patients are still being followed up 
in the outpatient clinic on a monthly basis for 
abstinence-oriented counseling. The satisfac-
tory and quick recovery in these patients so far 
seemed to be a reflection of their high level of 
motivation, absence of psychiatric symptoms, 
family support, intensive counseling and a 
relatively low severity of substance use (UN-
ODC, 2002). These factors have been shown 
to improve recovery, treatment adherence and 
attitudinal change. 
In conclusion, we suggest that seminars 
be organized for health workers on the use of 
pentazocine (and other analgesics) in sickle 
cell anaemia disease. Patients with chronic 
pain should also be counselled on the symp-
toms of dependence on analgesic drugs and 
to report same to their doctors immediately. 
Where not in existence, drug units (separate 
from the general psychiatric ward) should be 
established in all tertiary hospitals. Finally, 
legislation against indiscriminate sales of con-
trolled drugs should be enforced.
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